

Product Datasheet

IRF5 Antibody NB100-1092

Unit Size: 0.1 mg

Store at -20C. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 9

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB100-1092

Updated 9/9/2025 v.20.1

**Earn rewards for product
reviews and publications.**

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB100-1092



NB100-1092

IRF5 Antibody


Product Information	
Unit Size	0.1 mg
Concentration	0.5 mg/ml
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Target Molecular Weight	56 kDa

Product Description	
Description	Novus Biologicals Goat IRF5 Antibody (NB100-1092) is a polyclonal antibody validated for use in WB, ELISA, Flow and ChIP. Anti-IRF5 Antibody: Cited in 9 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Goat
Gene ID	3663
Gene Symbol	IRF5
Species	Human, Mouse
Reactivity Notes	Mouse reactivity reported in scientific literature (PMID: 22879997).
Specificity/Sensitivity	This antibody is expected to recognize all four reported isoforms (NP_002191.1; NP_116032.1; NP_001092097.1; NP_001092099.1). Reported variants NP_001092100.1, NP_001092101.1, NP_001092098.1, NP_001092097.1 represent identical protein: Reported variants NP_116032.1, NP_001092100.1 represent identical protein
Immunogen	Peptide with sequence C-QGPWPMHPAGMQ corresponding to C-Terminus according to NP_002191.1, NP_116032.1, NP_001092097.1, NP_001092099.1.


Product Application Details	
Applications	Western Blot, Flow Cytometry, Peptide ELISA, Chromatin Immunoprecipitation (ChIP), Knockdown Validated
Recommended Dilutions	Western Blot 0.3 - 1 ug/mL, Flow Cytometry, Peptide ELISA Detection limit 1:128000, Chromatin Immunoprecipitation (ChIP), Knockdown Validated
Application Notes	Western blot: Approx 55+60 kDa bands observed in Human spleen lysates and approx 65 kDa in lysates of cell line A549 (calculated MW of 57.8 kDa according to NP_001092099.1 and 56.0 kDa according to NP_116032.1; NP_001092097.2). Use in ChIP reported in scientific literature (PMID: 20237317). Use in Flow cytometry reported in scientific literature (PMID: 22879997).

Images


Western Blot: IRF5 Antibody [NB100-1092] - Western blot analysis of Human Spleen (A) and A549 cell lysate (B) + peptide (C), 35 ug protein in RIPA buffer. Antibody at 1 ug/mL. Detected by chemiluminescence




Western Blot: IRF5 Antibody [NB100-1092] - Endogenous IRF5 knockdown analysis. Ramos B cells were nucleofected with scrambled (Scr) or IRF5 (KD) siRNAs and lysates from same nucleofection run on multiple independent blots for comparative analysis of seven different commercially available alpha-IRF5 antibodies. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data are representative of three independent experiments. Image collected and cropped by CiteAb from the following publication (<https://www.nature.com/articles/srep31002>), licensed under a CC-BY license.




Western Blot: IRF5 Antibody [NB100-1092] - Comparative analysis of IRF5 protein expression between immortalized lymphoid cell lines by immunoblot. Endogenous IRF5 protein expression in lysates (T, THP-1; R, Ramos B cells; J, Jurkat T cells) was detected by running multiple independent blots for the analysis of antibody specificity; seven different commercially available alpha-IRF5 antibodies were evaluated. IRF5 expression was detected with the previously validated Cell Signaling antibody #3257 that is no longer available. beta-actin levels and apparent molecular weight standards are shown as loading controls and for size comparison, respectively. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data are representative of three independent experiments. Image collected and cropped by CiteAb from the following publication (<https://www.nature.com/articles/srep31002>), licensed under a CC-BY license.



Western Blot: IRF5 Antibody [NB100-1092] - Overexpression of IRF5 in MCF-7 & MDA-MB-231 cells sensitizes them to DNA damage-induced growth inhibition. A. Endogenous IRF expression was analyzed by Western blot in transformed mammary epithelial cell lines. Levels of β -actin are shown as loading controls. B. Western blot analysis of stable cell lines generated to overexpress retroviral pBIRF5. C. Cell survival was measured in MCF-7 & MDA-MB-231 pBabe cell lines by colony formation assay before & after treatment. Cells were treated with 0.1 or 1 μ M Doxorubicin (Dox) or 2, 5 & 10 Gy γ -IR. The number of colonies is plotted on the y-axis as percent of control; 100% represents the number of colonies in empty pBabe control lines. Data are expressed as mean \pm SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in pBabe versus pBIRF5 cell lines after each treatment; * denotes $P < 0.05$, ** $P < 0.001$. Image collected & cropped by CiteAb from the following publication (<http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3053>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: IRF5 Antibody [NB100-1092] - Comparative analysis of IRF5 protein expression between immortalized lymphoid cell lines by immunoblot. (A) qRT-PCR analysis of IRF5 transcript expression in immortalized lymphoid cell lines. Data is presented as relative expression after normalization to β -actin using the $\Delta\Delta$ Ct method. (B) Immunoblot analysis of endogenous IRF5 protein expression in immortalized cell lines. IRF5 expression was detected with the previously validated Cell Signaling antibody #3257 that is no longer available. β -actin levels & apparent molecular weight standards are shown as loading controls & for size comparison, respectively. (C) Experimental details for the comparative analysis of α -IRF5 antibody specificity by immunoblot analysis. (D) Same as in (B) except lysates (T, THP-1; R, Ramos B cells; J, Jurkat T cells) were run on multiple independent blots for the analysis of antibody specificity; seven different commercially available α -IRF5 antibodies were evaluated. (E) Same as in (D) except antibodies were evaluated by IRF5 knockdown analysis. Ramos B cells were nucleofected with scrambled (Scr) or IRF5 (KD) siRNAs & lysates from same nucleofection run on multiple independent blots for comparative analysis. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data (except in (C)) are representative of three independent experiments. Image collected & cropped by CiteAb from the following publication (<https://www.nature.com/articles/srep31002>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: IRF5 Antibody [NB100-1092] - Down-regulation of IRF5 protein expression by siRNAs alters sensitivity to DNA damage. A. MCF-12A cells were incubated with transfection reagent alone (mock-transfected), control Lamin A/C siRNAs or 5 nM IRF5 siRNAs once (IRF5 siRNA1) or twice (IRF5 siRNA2), as described in the Materials & methods. Western blot analysis shows > 70% reduction of endogenous IRF5 proteins after normalization to β -actin levels. B. Cells were exposed to 5 Gy IR or the same dose plus IFN- γ (IR/ γ) for 24 h. Percent of Annexin V-FITC stained positive cells is shown in the upper & lower right-hand quadrants. Representative histogram plots from three independent experiments performed in duplicate are shown. C. Same as in B, except cells were exposed to 1 μ M Dox or Dox & IFN- γ for five hours. Percent of Annexin V-FITC stained positive cells compared to control is plotted on y-axis. Data are expressed as mean \pm SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between cells transfected with Lamin A/C siRNAs (12Asicon) & IRF5 siRNAs (12AsilRF5) after each treatment; ** denotes $P < 0.001$. D. Cells were treated with the indicated doses of Dox or IR after siRNA transfection. Number of colonies is plotted on y-axis as percent of control. A total of 100% represents the number of colonies in control untreated 12Asicon cells. Data are expressed as mean \pm SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in 12Asicon versus 12AsilRF5 cells after each treatment; * denotes $P < 0.05$. Image collected & cropped by CiteAb from the following publication (<http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3053>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: IRF5 Antibody [NB100-1092] - Comparative analysis of IRF5 protein expression between immortalized lymphoid cell lines by immunoblot. (A) qRT-PCR analysis of IRF5 transcript expression in immortalized lymphoid cell lines. Data is presented as relative expression after normalization to β -actin using the $\Delta\Delta$ Ct method. (B) Immunoblot analysis of endogenous IRF5 protein expression in immortalized cell lines. IRF5 expression was detected with the previously validated Cell Signaling antibody #3257 that is no longer available. β -actin levels & apparent molecular weight standards are shown as loading controls & for size comparison, respectively. (C) Experimental details for the comparative analysis of α -IRF5 antibody specificity by immunoblot analysis. (D) Same as in (B) except lysates (T, THP-1; R, Ramos B cells; J, Jurkat T cells) were run on multiple independent blots for the analysis of antibody specificity; seven different commercially available α -IRF5 antibodies were evaluated. (E) Same as in (D) except antibodies were evaluated by IRF5 knockdown analysis. Ramos B cells were nucleofected with scrambled (Scr) or IRF5 (KD) siRNAs & lysates from same nucleofection run on multiple independent blots for comparative analysis. Arrows indicate detection of an appropriately sized band(s) corresponding to IRF5. Data (except in (C)) are representative of three independent experiments. Image collected & cropped by CiteAb from the following publication (<https://www.nature.com/articles/srep31002>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: IRF5 Antibody [NB100-1092] - Overexpression of IRF5 in MCF-7 & MDA-MB-231 cells sensitizes them to DNA damage-induced growth inhibition. A. Endogenous IRF expression was analyzed by Western blot in transformed mammary epithelial cell lines. Levels of β -actin are shown as loading controls. B. Western blot analysis of stable cell lines generated to overexpress retroviral pBIRF5. C. Cell survival was measured in MCF-7 & MDA-MB-231 pBabe cell lines by colony formation assay before & after treatment. Cells were treated with 0.1 or 1 μ M Doxorubicin (Dox) or 2, 5 & 10 Gy γ -IR. The number of colonies is plotted on the y-axis as percent of control; 100% represents the number of colonies in empty pBabe control lines. Data are expressed as mean \pm SD of three independent experiments performed in duplicate. Statistical significance was determined by comparing the difference between colonies in pBabe versus pBIRF5 cell lines after each treatment; * denotes $P < 0.05$, ** $P < 0.001$. Image collected & cropped by CiteAb from the following publication (<http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3053>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Comparative analysis of IRF5 protein expression between immortalized lymphoid cell lines using flow cytometry. (A) Experimental details for the comparative analysis of α -IRF5 antibody specificity by flow cytometry. (B) Representative histogram plots from flow cytometry analysis of intracellular IRF5 in immortalized cell lines using different α -IRF5 antibodies. Data are representative of three independent experiments. Ctrl-iso, matched isotype antibodies used as non-specific controls. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/27481535>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Bi Xiaohui, Hameed Meera, Mirani Neena et al. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. *Breast Cancer Res* 2011-01-01 [PMID: 22053985] (WB, Human)

Li D, De S, Li D et al. Specific detection of interferon regulatory factor 5 (IRF5): A case of antibody inequality. *Sci Rep* 2016-08-02 [PMID: 27481535]

Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. *J Biol Chem* 2001-06-29 [PMID: 11303025]

Hanke ML, Angle A, Kielian T. MyD88-Dependent Signaling Influences Fibrosis and Alternative Macrophage Activation during *Staphylococcus aureus* Biofilm Infection *PLoS One* 2012-01-01 [PMID: 22879997] (FLOW, Mouse)

Ye L, Peng JS, Wang X, Wang YJ, Luo GX, Ho WZ. Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. *J Viral Hepat*;15(4):261-70. 2008-04-01 [PMID: 18307590]

Ning S, Huye LE, Pagano JS. Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit. *J Virol*;79(18):11671-6. 2005-09-01 [PMID: 16140744]

Krausgruber T, Saliba D, Ryzhakov G, Lanfrancotti A, Blazek K, Udalova IA. IRF5 is required for late-phase TNF secretion by human dendritic cells. *Blood*;115(22):4421-30. 2010-06-03 [PMID: 20237317] (Chemotaxis)

Hu G, Barnes BJ. IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. *J Biol Chem*;284(5):2767-77. 2009-01-30 [PMID: 19028697]

Graham RR et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. *Proc Natl Acad Sci U S A*;104(16):6758-63. 2007-04-17 [PMID: 17412832]





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB100-1092

NBL1-12034	IRF5 Overexpression Lysate
NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF017	Rabbit anti-Goat IgG Secondary Antibody [HRP (Horseradish Peroxidase)]
HAF109	Donkey anti-Goat IgG Secondary Antibody [HRP (Horseradish Peroxidase)]
NB410-28088-1mg	Goat IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-1092

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications



